Platelet-activating factor podoplanin: from discovery to drug development.

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Tumor cell-induced platelet aggregation is a key mechanism in hematogenous metastasis.
• Podoplanin (Aggrus) is a glycoprotein expressed on tumor cells that mediates platelet aggregation.
• Podoplanin binds to its platelet receptor, C-type lectin-like receptor 2 (CLEC-2), promoting metastasis.

Purpose of the Study:

• To review the role of platelets in metastasis formation.
• To summarize the function of podoplanin in pathological and physiological contexts.
• To explore the potential of developing podoplanin-targeting drugs for cancer therapy.

Main Methods:

• Cloning of highly metastatic cell lines and development of neutralizing monoclonal antibodies (mAbs).
• Identification of podoplanin as the antigen recognized by neutralizing mAbs.
• Analysis of podoplanin mutants and neutralizing anti-podoplanin mAbs to identify functional domains (PLAG3, PLAG4) involved in CLEC-2 binding.

Main Results:

• Ectopic expression of podoplanin confers platelet-aggregating abilities and metastatic potential.
• The platelet aggregation-stimulating (PLAG) domains, specifically PLAG3 and PLAG4, are crucial for CLEC-2 binding.
• Neutralizing mAbs targeting PLAG3 or PLAG4 inhibit podoplanin-induced platelet aggregation and metastasis by blocking podoplanin-CLEC-2 interaction.

Conclusions:

• Podoplanin's PLAG domains are critical for mediating platelet aggregation and hematogenous metastasis.
• Targeting the podoplanin-CLEC-2 interaction presents a promising therapeutic strategy for inhibiting cancer metastasis.
• Further research into podoplanin-targeting drugs could offer new avenues for cancer treatment.